2019
Hepatic resection of solitary HCC in the elderly: A unique disease in a growing population
Zarour LR, Billingsley KG, Walker BS, Enestvedt CK, Orloff SL, Maynard E, Mayo SC. Hepatic resection of solitary HCC in the elderly: A unique disease in a growing population. The American Journal Of Surgery 2019, 217: 899-905. PMID: 30819401, DOI: 10.1016/j.amjsurg.2019.01.030.Peer-Reviewed Original ResearchConceptsSolitary hepatocellular carcinomaPrognostic nutritional indexHepatic resectionElderly patientsUnique diseaseLow prognostic nutritional indexMedian Child-Pugh scoreTumor size 5Child-Pugh scoreGrade III complicationsHalf of patientsRecurrence-free survivalSolitary HCCExtrahepatic recurrenceProspective databaseR0 resectionIntrahepatic recurrenceMajor hepatectomyMedian survivalOverall survivalViral hepatitisLow morbidityMedian ageClinicopathologic dataClinicopathologic differences
2011
S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma
Leichman L, Goldman B, Bohanes P, Lenz H, Thomas C, Billingsley K, Corless C, Iqbal S, Gold P, Benedetti J, Danenberg K, Blanke C. S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2011, 29: 4555-4560. PMID: 22025151, PMCID: PMC3236655, DOI: 10.1200/jco.2011.36.7490.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDrug Administration ScheduleEsophageal NeoplasmsEsophagectomyFemaleFluorouracilHumansMaleMiddle AgedNeoadjuvant TherapyOrganoplatinum CompoundsOxaliplatinRadiotherapy, AdjuvantConceptsPathologic complete responseEsophageal adenocarcinomaOverall survivalNeoadjuvant therapyExternal beam radiation therapyPhase II ClinicalProspective exploratory analysisPatient underwent surgeryPrimary end pointProgression-free survivalSouthwest Oncology GroupAdvanced esophageal adenocarcinomaSingle-arm trialGy/dNeoadjuvant oxaliplatinSystemic regimenPreoperative therapyR0 resectionUnderwent surgeryOncology GroupPCR rateComplete responseImproved survivalFuture trialsGrade 3
2010
Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors
Ellis M, Cassera M, Vetto J, Orloff S, Hansen P, Billingsley K. Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors. Hepato Pancreato Biliary 2010, 13: 59-63. PMID: 21159105, PMCID: PMC3019543, DOI: 10.1111/j.1477-2574.2010.00242.x.Peer-Reviewed Original ResearchConceptsOverall survival rateIntrahepatic cholangiocarcinomaR0 resectionSurgical treatmentR1/R2 resectionResectable intrahepatic cholangiocarcinomaPostoperative liver failureMainstay of treatmentOptimal patient selectionPostoperative complication rateKaplan-Meier methodCox hazard modelPreoperative hypoalbuminaemiaReplete patientsR2 resectionSurgical mortalityComplication rateSurgical resectionSurgical therapyWorse survivalClinicopathologic characteristicsLiver failureOperative detailsPrognostic factorsRecurrence outcomesAdjuvant therapy and survival after resection of pancreatic adenocarcinoma
Mayo S, Austin D, Sheppard B, Mori M, Shipley D, Billingsley K. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma. Cancer 2010, 116: 2932-2940. PMID: 20336787, DOI: 10.1002/cncr.25082.Peer-Reviewed Original ResearchConceptsAdjuvant therapyPancreatic adenocarcinomaOverall survivalAdjuvant treatmentCox proportional hazards modelMedian overall survivalKaplan-Meier methodMedical record reviewPopulation-based cohortOngoing clinical trialsState Cancer RegistryProportional hazards modelPaucity of dataAdjuvant chemoradiationCurative intentR0 resectionMedian survivalPerformance statusComplete resectionRecord reviewCancer RegistryPathologic stageClinical trialsRegistry dataHazards model